Aevice Wheeze Detection Module
Aevice Health Pte. , Ltd. · Decision date Sep 25, 2026
What did the FDA decide?
The FDA recorded a substantially equivalent (SESE) decision on September 25, 2026 for the Aevice Wheeze Detection Module, submitted by Aevice Health Pte., Ltd. under K260140. The submission is a traditional 510(k), not reviewed by a third party, with no combination product status and no authorized predetermined change control plan. The device is classified under 21 CFR 868.1900 as a diagnostic pulmonary-function interpretation calculator, Class II, product code PHZ, in the anesthesiology specialty.
The cleared device is stand-alone software that analyzes lung sound recordings from compatible FDA-cleared electronic stethoscopes and flags recordings where wheeze is suspected; the summary names Tyto Insights for Wheeze Detection (K232237) as the predicate. The summary states the subject device is prescription-only while the predicate is over-the-counter, and that the subject device lacks the predicate's hardware components. The source does not include performance data, so clinical accuracy is not assessed here.
The public record shows a decision date of September 25, 2026, while the FDA letter excerpt lists the submission as dated and received August 21, 2026, and the database page lists a received date of January 20, 2026; these dates are not reconciled in the source.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Anesthesiology
- Decision date
- Sep 25, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260140
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Aevice Health Pte. , Ltd.
- Product code
- PHZ
- Decision code
- SESE
- Decision date
- Sep 25, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Abnormal Breath Sound Device.
- Applicant
- Aevice Health Pte. , Ltd.
- Product code
- PHZ
- FDA device class
- 2
FDA decision timeline
K260140 received
Application receipt date recorded by FDA.
K260140 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Aevice Health Pte. , Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Singapore
Sources and methodology
- Original FDA record: K260140
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records